- Home
- RA vs HUMA Comparison
RA vs HUMA Comparison
Compare RA & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RA
- HUMA
- Stock Information
- Founded
- RA 2016
- HUMA 2004
- Country
- RA United States
- HUMA United States
- Employees
- RA N/A
- HUMA N/A
- Industry
- RA Investment Managers
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- RA Finance
- HUMA Health Care
- Exchange
- RA Nasdaq
- HUMA Nasdaq
- Market Cap
- RA 739.7M
- HUMA 691.8M
- IPO Year
- RA N/A
- HUMA N/A
- Fundamental
- Price
- RA $13.14
- HUMA $4.84
- Analyst Decision
- RA
- HUMA Strong Buy
- Analyst Count
- RA 0
- HUMA 7
- Target Price
- RA N/A
- HUMA $12.71
- AVG Volume (30 Days)
- RA 280.8K
- HUMA 3.2M
- Earning Date
- RA 01-01-0001
- HUMA 11-08-2024
- Dividend Yield
- RA 14.73%
- HUMA N/A
- EPS Growth
- RA N/A
- HUMA N/A
- EPS
- RA N/A
- HUMA N/A
- Revenue
- RA N/A
- HUMA N/A
- Revenue This Year
- RA N/A
- HUMA N/A
- Revenue Next Year
- RA N/A
- HUMA $5,405.72
- P/E Ratio
- RA N/A
- HUMA N/A
- Revenue Growth
- RA N/A
- HUMA N/A
- 52 Week Low
- RA $11.89
- HUMA $2.43
- 52 Week High
- RA $17.32
- HUMA $9.97
- Technical
- Relative Strength Index (RSI)
- RA 36.75
- HUMA 40.76
- Support Level
- RA $13.29
- HUMA $4.75
- Resistance Level
- RA $13.63
- HUMA $6.11
- Average True Range (ATR)
- RA 0.14
- HUMA 0.40
- MACD
- RA -0.03
- HUMA -0.04
- Stochastic Oscillator
- RA 20.49
- HUMA 6.25
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities (collectively, Real Asset Companies and Issuers). The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.